SAG
ALNY icon

SageView Advisory Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

SageView Advisory Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-398
Closed -$158K – 644
2025
Q4 		$158K Buy
+398
New +$176K 0.01% 666

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SageView Advisory Group's ALNY Position: Q1 2026 in Review

SageView Advisory Group sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 398 shares — an estimated $158K sold.

SageView Advisory Group first reported a position in ALNY in Q4 2025 and held it in 1 quarter. The position peaked at $158K in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • SageView Advisory Group reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 398 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $158K.
  • SageView Advisory Group first reported a position in Alnylam Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Alnylam Pharmaceuticals position peaked at $158K in Q4 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.